Abstract
The recent introduction of new therapeutic agents has proven alternative options in the management of patients with metastatic castration-resistant prostate cancer (mCRPC). Moreover, other novel agents are being studied and developed. Bone represents the most common site of recurrence in mCRPC, occurring in more than 80 % of cases. The evaluation of treatment efficacy in bone metastatic prostate cancer (PC) is mainly focused on the assessment of patient outcomes, but the behavior of bone metastases and their changes due to the therapy are also of great interest. The impressive development of technologies offers today various options for describing the skeletal changes caused by metastases before, during, and after treatments. At present, in clinical practice, the only laboratory test currently used to measure metastatic bone progression remains prostate-specific antigen (PSA). Great importance has been progressively assumed by new modalities of metabolic imaging, such as 18F fluoride, 18F/11C choline, and 18F FDG positron emission tomography (PET)/computed tomography (CT) that are flanking the traditional bone scan (BS) with 99mTc phosphonates, both with planar acquisition and single-photon emission computed tomography (SPECT). In addition, radiology, besides CT, is proposing the high performance of multimodality magnetic resonance imaging (MRI) that seems to guarantee a very high accuracy in evaluating skeletal involvement.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Kirby M, Hirst C, Crawford ED (2011) Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 65:1180–1192
Portenoy RK, Koh M (2010) Cancer pain syndromes. In: Bruera E, Portenoy RK (eds), Cancer pain. Assessment and management, vol 4. Cambridge University Press pp 53–88
Van Herk R, van Dijk M, Baar FPM et al (2007) Observational scales for pain assessment in older adults with cognitive impairments or communication difficulties. Nurs Res 56:34–43
Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223
Sartor O, Coleman R, Nilsson S et al (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15:738–746
James ND, Pirrie S, Brown JE et al (2013) Clinical outcomes in patients with castraterefractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). J Clin Oncol 31:abstr LBA5000
Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391–420
Fohr B, Dunstan CR, Seibel MJ (2003) Clinical review 165: markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 88:5059–5075
Tamada T, Sone T, Tomomitsu T et al (2001) Biochemical markers for the detection of bone metastasis in patients with prostate cancer, diagnostic efficacy and the effects of hormonal therapy. J Bone Miner Metab 19:45–51
Jung K, Lein M (2002) Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis. J Clin Oncol 20:850–856
Koizumi M, Yonese J, Fukui I, Ogata E (2001) The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87:348–351
Zafeirakis AG, Papatheodorou GA, Limouris GS (2010) Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases. Nucl Med Commun 31:249–253
Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E (2007) Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 178(3 Pt 1):849–853
Zafeirakis AG, Papatheodorou GA, Arhontakis A et al (2010) Predictive implications of bone turnover markers after palliative treatment with (186)Re-HEPD in hormone-refractory prostate cancer with painful osseous metastases. Nucl Med Commun 31:249–253
Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR (2006) Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12(1):3361–7.99–100
Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F (2007) Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 70(2):315–319
Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. Clin Oncol 23(22):4925–4935
Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F (2007) Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 70(2):315–319)
Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, Corn PG (2012) Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Cancer 107(9):1547–1553
Metwalli AR, Rosner IL, Cullen J, Chen Y, Brand T, Brassell SA, Lesperance J, Porter C, Sterbis J, McLeod DG (2014) Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer. Urol Oncol 32(6):761–768
Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, Iversen P (2006) Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66(5):503–513
Payne H, Cornford P (2011) Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol 29:593–601
Hillner BE, Siegel BA, Hanna L, Duan F, Quinn B, Shields AF (2015) 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry. J Nucl Med 56:222–228
Thuret R, Massard C, Gross-Goupil M, Escudier B, Di Palma M, Bossi A, de Crevoisier R, Chauchereau A, Fizazi K (2008) The postchemotherapy PSA surge syndrome. Ann Oncol 19:1308–1311
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159
Galasko CS (1995) Diagnosis of skeletal metastases and assessment of response to treatment. Clin Orthop Relat Res 312:64–75
Costelloe CM, Chuang HH, Madewell JE, Ueno NT (2010) Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer Educ 1:80–92
Bauerle T, Semmler W (2009) Imaging response to systemic therapy for bone metastases. Eur Radiol 19:2495–2507
Messiou C, Cook G, Reid AH et al (2011) The CT flare response of metastatic bone disease in prostate cancer. Acta Radiol 52:557–561
Hwang S, Panicek DM (2007) Magnetic resonance imaging of bone marrow in oncology, Part 2. Skeletal Radiol 36:1017–1027
Lecouvet FE, Larbi A, Pasoglou V et al (2013) MRI for response assessment in metastatic bone disease. Eur Radiol 23:1986–1997
Pasoglou V, Michoux N, Peeters F, Larbi A, Tombal B, Selleslagh T et al (2015) Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. Radiology 275:155–166
Koh DM, Takahara T, Imai Y, Collins DJ (2007) Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. Magn Reson Med Sci 6:211–224
Lecouvet FE, Geukens D, Stainier A, Jamar F, Jamart J, d’Othee BJ et al (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25:3281–3287
Ketelsen D, Rothke M, Aschoff P, Merseburger AS, Lichy MP, Reimold M et al (2008) Detection of bone metastasis of prostate cancer – comparison of whole-body MRI and bone scintigraphy. Rofo 180:746–752
Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68–75
Luboldt W, Kufer R, Blumstein N, Toussaint TL, Kluge A, Seemann MD et al (2008) Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology 249:1017–1025
Venkitaraman R, Cook GJ, Dearnaley DP, Parker CC, Khoo V, Eeles R et al (2009) Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J Med Imaging Radiat Oncol 53:241–247
Wang X, Zhang C, Jiang X (2009) Prospective study of bone metastasis from prostate cancer: comparison between large field diffusion-weighted imaging and bone scintigraphy. Chinese J Radiol 43:131–135
Gutzeit A, Doert A, Froehlich JM, Eckhardt BP, Meili A, Scherr P et al (2010) Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 39:333–343
Mosavi F, Johansson S, Sandberg DT, Turesson I, Sorensen J, Ahlstrom H (2012) Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol 199:1114–1120
Stecco A, Lombardi M, Leva L, Brambilla M, Negru E, Delli Passeri S et al (2013) Diagnostic accuracy and agreement between whole-body diffusion MRI and bone scintigraphy in detecting bone metastases. Radiol Med 118:465–475
Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B et al (2014) Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer 50:1617–1627
Reischauer C, Froehlich JM, Koh DM et al (2010) Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps-initial observations. Radiology 257:523–531
Messiou C, Collins DJ, Giles S et al (2011) Assessing response in bone metastases in prostate cancer with diffusion weighted MRI. Eur Radiol 21:2169–2177
Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG et al (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:11–20
Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I (2006) The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47:287–297
Bombardieri E, Bombardieri E, Setti L, Kirienko M, Antunovic L, Guglielmo P et al (2015) Which metabolic imaging, besides bone scan with 99mTc-phosphonates, for detecting and evaluating bone metastases in prostatic cancer patients? An open discussion. The Quarterly J Nucl Med Mol Imaging 4:381–399
Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A et al (2010) When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 57:551–558
Hillner BE, Siegel BA, Hanna L et al (2015) 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry. J Nucl Med 56:222–228
Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ et al (2012) Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol 30:519–524
Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H et al (2012) A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 62:78–84
Gamez-Cenzano C, Pino-Sorroche F (2014) Standardization and quantification in FDG-PET/CT imaging for staging and restaging of malignant disease. PET Clin 9:117–127
Garcia JR, Moreno C, Valls E, Cozar P, Bassa P, Soler M, Alvarez-Moro FJ, Moragas M, Riera E (2015) Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer. Rev Esp Med Nucl Imagen Mol 34:155–161
Poulsen MH, Petersen H, Høilund-Carlsen PF, Jakobsen JS, Gerke O, Karstoft J, Steffansen SI, Walter S (2014) Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT. BJU Int 114:818–823
Iagaru A, Mittra E, Dick DW, Gambhir SS (2012) Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol 14:252–259
Damle NA, Bal C, Bandopadhyaya GP, Kumar L, Kumar P, Malhotra A, Lata S (2013) The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. Jpn J Radiol 31:262–269
Palmedo H, Marx C, Ebert A, Kreft B, Ko Y, Türler A, Vorreuther R, Göhring U, Schild HH, Gerhardt T, Pöge U, Ezziddin S, Biersack HJ, Ahmadzadehfar H (2014) Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging 41:59–67
Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, Mievis F, Aerts J, Waltregny D, Jerusalem G, Hustinx R (2011) 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 32:168–176
Takesh M, Odat Allh K, Adams S, Zechmann C (2012) Diagnostic role of (18)F-FECH-PET/CT compared with bone scan in evaluating the prostate cancer patients referring with biochemical recurrence. ISRN Oncol 2012:815234
Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, Loidl W, Pirich C, Fogelman I, Langsteger W (2010) The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 12:98–107
Langsteger W, Balogova S, Huchet V, Beheshti M, Paycha F, Egrot C, Janetschek G, Loidl W, Nataf V, Kerrou K, Pascal O, Cussenot O, Talbot JN (2011) Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging 55:448–457
Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, Loidl W, Pirich C, Fogelman I, Langsteger W (2009) The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 11:446–454
McCarthy M, Siew T, Campbell A, Lenzo N, Spry N, Vivian J, Morandeau L (2011) 18F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging 38:14–22
Fuccio C, Castellucci P, Schiavina R, Santi I, Allegri V, Pettinato V, Boschi S, Martorana G, Al-Nahhas A, Rubello D, Fanti S (2010) Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med 24:485–492
Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L, Messa C (2012) [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 39:13–26
Mohsen B, Giorgio T, Rasoul ZS, Werner L, Ali GR, Reza DK, Ramin S (2013) Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int 112:1062–1072
Caffo O, Maines F, Donner D, Veccia A, Chierichetti F, Galligioni E (2014) Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients. Clin Genitourin Cancer 12:312–316
De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio SL, Menna C et al (2015) (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging 2015;42:1276–1283
De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E et al (2014) Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget 5:12448–12458
Ceci F, Castellucci P, Graziani T, Schiavina R, Renzi R, Borghesi M et al (2015) C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. Eur J Nucl Med Mol Imaging
Messiou C, Cook G, deSouza MN (2009) Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer 101:1225–1232
Wade AA, Scott JA, Kuter I, Fischman AJ (2006) Flare response in 18F-fluoride ion PET bone scanning. AJR 186:1783–1786
Levenson RM, Sauerbrunn BJ, Bates HR, Newman RD, Eddy JL, Ihde DC (1983) Comparative value of bone scintigraphy and radiography in monitoring tumour response in systemically treated prostatic carcinoma. Radiology 146:513–518
Pollen JJ, Witztum KF, Ashburn WL (1984) The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Am J Roentgenol 142:773–776
Mitsui Y, Shiina H, Yamamoto Y, Haramoto M, Arichi N, Yasumoto H, Kitagaki H, Igawa M (2012) Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int 110:E628–E6234
Shimizu N, Masud H, Yamanaka H, Oriuchi N, Inoue T, Endo K (1999) Fluorodeoxyglucose positron emission tomography scan of prostate cancer bone metastases with flare reaction after endocrine therapy. J Urol 161:608–609
Jadvar H (2011) Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med 52:81–89
Wade AA, Scott JA, Kuter I, Fischman AJ (2006) Flare response in 18F-fluoride ion PET bone scanning. AJR Am J Roentgenol 186:1783–1786
McNamara MA, George DJ (2015) Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. BMC Cancer 15:371
Jadvar M, Desai B, Si L, Groshen S, Mills J, Murray R et al (2015) Prediction of hormonal resistance in metastatic prostate cancer with FDG PET/CT. J Nucl Med 56:1451
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B; Zoledronic Acid Prostate Cancer Study Group (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA (2004) Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520
Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, Eymard JC, Falcon S, Calabrò F, James N, Bodrogi I, Harper P, Wirth M, Berry W, Petrone ME, McKearn TJ, Noursalehi M, George M, Rozencweig M (2009) Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 27:5431–5438
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Frohlich MW, Schellhammer PF (2010) IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO (2010) TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983–992
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS (2012) AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148. Erratum in N Engl J Med 368:584
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737–746
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O’Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163–1177
Parker C, Gillessen S, Heidenreich A, Horwich A; ESMO Guidelines Committee (2015) Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v69–77
https://www.auanet.org/common/pdf/education/clinical-guidance/Prostate-Cancer.pdf
http://www.nccn.org/professionals/physiciangls/pdf/prostate.pdf
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B (2015) Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26:1589–1604
Evangelista L, Bertoldo F, Boccardo F, Conti G, Menchi I, Mungai F et al (2016) Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. Eur J Nucl Med Mol Imaging 2016;43(8):1546–62
Acknowledgments
The authors are grateful to Ms. Annaluisa De Simone Sorrentino for her collaboration in preparing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Bombardieri, E. et al. (2017). Approaches for Assessment of Response of Bone Metastases to Therapies. In: Bertoldo, F., Boccardo, F., Bombardieri, E., Evangelista, L., Valdagni, R. (eds) Bone Metastases from Prostate Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-42327-2_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-42327-2_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42326-5
Online ISBN: 978-3-319-42327-2
eBook Packages: MedicineMedicine (R0)